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Abstract
Scope—Moringa oleifera (moringa) is tropical plant traditionally used as an antidiabetic food. It 
produces structurally unique and chemically stable moringa isothiocyanates (MICs) that were 
evaluated for their therapeutic use in vivo.
Methods and results—C57BL/6L mice fed very high fat diet (VHFD) supplemented with 5% 
moringa concentrate (MC, delivering 66 mg/kg/d of MICs) accumulated fat mass, had improved 
glucose tolerance and insulin signaling, and did not develop fatty liver disease compared to 
VHFD-fed mice. MC-fed group also had reduced plasma insulin, leptin, resistin, cholesterol, 
IL-1β, TNFα, and lower hepatic glucose-6-phosphatase (G6P) expression. In hepatoma cells, MC 
and MICs at low micromolar concentrations inhibited gluconeogenesis and G6P expression. MICs 
and MC effects on lipolysis in vitro and on thermogenic and lipolytic genes in adipose tissue in 
vivo argued these are not likely primary targets for the anti-obesity and anti- diabetic effects 
observed.
Conclusion—Data suggest that MICs are the main anti-obesity and anti-diabetic bioactives of 
MC, and that they exert their effects by inhibiting rate-limiting steps in liver gluconeogenesis 
resulting in direct or indirect increase in insulin signaling and sensitivity. These conclusions 
suggest that MC may be an effective dietary food for the prevention and treatment of obesity and 
type 2 diabetes.
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Mechanistic understanding of effective dietary therapeutics in the prevention of type 2 
diabetes (T2D) and obesity remain important goals in lifestyle-oriented healthcare. Edible 
leaves from the moringa tree (Moringa oleifera Lam.) have been used as an antidiabetic 
food throughout the centuries, but only scantly explored scientifically [1]. Moringa's 
nutritional profile makes it well-suited for integration into a diet-based T2D prevention 
program. In addition, moringa leaves contain an abundance of secondary metabolites, 
principally polyphenols and four unique moringa isothiocyanates (MICs), with strong 
biological activity. MICs contain the same pharmacophore (R–N=C=S) as isothiocyanates 
(ITCs) from broccoli (e.g. sulforaphane, SF) and other cruciferous vegetables, but differ 
from aliphatic ITCs, such as SF, by the presence of an aromatic ring and rhamnose moiety. 
Emerging evidence has suggested MICs are the principal therapeutically active constitutes 
found in moringa. Specifically, MICs were shown to reduce inflammatory expression in 
RAW macrophages [2-4]; and in rodent models, reduce nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) expression, myelomal growth [5], and blood pressure 
[6]. ITCs, particularly SF, have been thoroughly researched through pre-clinical, clinical and 
epidemiological studies [7-9] and advocated for dietary health prevention of cancer and 
other diseases. ITCs are potent inducers of phase II detoxifying enzymes and subsequently 
confer protection against oxidative stress and chronic inflammation [10].
Despite strong evidence of 1) chronic inflammation as an underlying cause of cancer and 
T2D, and 2) effectiveness of ITCs in the prevention of cancer, the use of ITC-rich foods as 
therapeutics in T2D remains virtually unknown. Recently, SF supplementation was shown to 
reduce insulin, inflammatory markers and LDL levels in T2D patients [11-13]. A major 
drawback to a therapeutic use of cruciferous ITCs is their inherent chemical instability [14]. 
Cruciferous ITCs are volatile oils, appearing only transiently after conversion from their 
precursor molecules, glucosinolates, by endogenous plant or exogenous microbial 
thioglucosidase (myrosinase) following plant tissue damage by injury or digestion.
MICs formed in moringa leaves are chemically unique due to the presence of their sugar 
moiety, and thus have a larger molecular weight, solid physical state, and presumably 
greater chemical stability compared to volatile cruciferous ITCs. Research on MICs remains 
very scarce compared to SF, yet emerging studies have shown MICs bear equal or stronger 
biological activity than other ITCs [3, 5, 15]. It is conceivable that moringa may be a 
superior alternative to broccoli as a source of stable ITCs [2] to prevent chronic diseases, 
particularly in tropical regions of the world where moringa trees grow and T2D and obesity 
rates are climbing [16-18].
Recently, we described a simple and effective method for production of a food-grade, MIC-
rich moringa concentrate (MC), made from extracting freshly crushed leaves in water [2]. In 
this study, we evaluated the effects of MC on metabolic and inflammatory dysregulation in 
diet-induced obese C57BL/6J mice and demonstrated that MICs are the primary 
pharmacological contributors to the observed effects. Trying to establish the mechanism of 
action of MICs, we investigated the effect of MC and MICs on in vitro gluconeogenesis in 
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liver cells and fat oxidation in adipocytes, and performed short-term in vivo studies on acute 
oral glucose tolerance and indirect calorimetry.
2. Materials and methods
2.1 Materials
Preparation of MC and isolation and quantification of MIC-1 (4-[(α-L-
rhamnosyloxy)benzyl]isothiocyanate) and MIC-4 (4-[(4-O-acetyl-α-L-
rhamnosyloxy)benzyl]isothiocyanate) was performed according to the previously described 
protocols with minor modifications [2]. Briefly, fresh moringa leaves were blended in 25°C 
water (1g leaves: 5 mL water), allowed to sit at 25°C for 30 min, centrifuged (only in the 
case of MC for the 5% diet), filtered, and lyophilized. The percent of MICs concentrated in 
MC batches ranged from ~1-3% due to natural variations in the starting plant material and 
whether the centrifugation step was included in the preparation of MC. Elimination of the 
centrifugation step increased the concentration of MICs recovered in MC. Therefore, the 
percent of MC incorporated into the mouse diets was adjusted and standardized to deliver 
800 mg of MICs/kg of food. In the long-term study, the very high-fat diet (VHFD) (60% 
kcal from fat) contained 5% MC, of which 1.66% were MICs (1.15% MIC-1 and 0.51% 
MIC-4) and the diet in the metabolic chamber study contained 3.3% MC, of which 2.40% 
were MICs (1.48% MIC-1 and 0.92% MIC-4). Both diets were formulated by Research 
Diets (New Brunswick, NJ) to be isocaloric for fat, protein and carbohydrate content (Suppl. 
Tables 1 & 2).
2.2 Animals
Three month study—Twenty-four male C57BL/6J mice at 5 weeks of age were obtained 
from Jackson Laboratories (Bar Harbor, ME). Mice were acclimated for 9 d and housed 4 
animals per cage under a 12-h light/dark cycle, with ad libitum access to water and a VHFD 
or VHFD + 5% MC for twelve weeks. Body weight and food intake was recorded weekly. 
Food intake was estimated as follows: [total food consumed per cage]/[mice per cage]×[d of 
food consumption]. Body composition was determined at 4, 8, and 12 weeks by magnetic 
resonance imaging using an EchoMRI-100 instrument (Echo Medical Systems, Houston, 
TX). Mice were removed from group cages and placed in clean individual cages. At the end 
of the study mice were euthanized with carbon dioxide. Blood and tissues (liver, inguinal 
fat, gastrocnemius muscle and ileum) were collected immediately and preserved at −80 °C. 
The animal protocol was approved by the Comparative Medicine Resources and the Office 
of Research and Sponsored Programs from Rutgers University, NJ, USA.
Two week indirect calorimetry study—Twenty-four male C57BL/6J mice at 4 weeks 
of age were purchased from Jackson Laboratories. After exit from quarantine, mice were 
given the VHFD and placed in training cages (TSE Systems, Chesterfield, MO) for one 
week. Then, they were transferred to metabolic chambers for one week to establish baseline 
values. Mice were weighed and body composition measured before randomization into 
treatment groups. Twelve mice per group were given a VHFD or VHFD + 3.3% MC for an 
additional week before returning to their home cages. Food intake, body weight, rearing 
activity, VO2 consumption and CO2 production were determined. The animal protocol was 
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approved by the Pennington Biomedical Research Center Institutional Animal Care and Use 
Committee.
2.3 Oral glucose tolerance test (OGTT)
Mice in the three month study were first fasted overnight before fasting glycemic levels 
were recorded using a glucometer (AlphaTRAK® 32004-02, Abbott Animal Health, Abbott 
Park, IL) and gavaged with 2 g/kg of glucose at weeks 4, 8 and 12 weeks of treatment. An 
additional six mice on the VHFD at the same age were gavaged with 300 mg/kg of 
metformin (positive control) 3 h prior to glucose gavage. Glycemic levels were measured at 
intervals up to 120 min.
2.3.1 Acute OGTT—Fifteen male C57BL/6J mice were purchased, acclimated and housed 
as described in the 3 month study. Mice were fed ad libitum a VHFD for 12 weeks. The 
OGTT was performed as described above except for gavage treatements of 2 g/kg of MC (n 
= 6), water (vehicle; n = 6), or 300 mg/kg of metformin (n = 3).
2.4 Blood chemistry analysis
Animals were fasted overnight and trunk blood was collected immediately after 
euthanization. Samples were collected in tubes with EDTA and plasma was aliquotted into 
cryovials and stored at −80 °C for analysis. Insulin, leptin, resistin, interleukin-1 beta 
(IL-1β) and tumor necrosis factor alpha (TNFα) were measured using a multiplex assay 
(Millipore, Temecula, CA) measured on a Luminex 200 (Luminex, Austin, TX). Total 
cholesterol and triglycerides (TG) were assayed on a DxC 600 Pro (Beckman Coulter, Inc., 
Indianapolis IN).
2.5 Liver histology, total lipid extraction, cholesterol and TG levels
Randomly selected liver sections were fixed in 10% neutral buffered formalin for 48 h, then 
processed and embedded in Paraplast. Six-micrometer sections were cut and stained in 
hematoxylin and eosin. A diagnosis of fatty liver was made based on the presence of macro 
or microvesicular fat > 5% of the hepatocytes in a given slide. Total lipid content of liver 
was determined by Folch's method [19]. Briefly, liver (~300 mg) was extracted 20:1 (v/w) 
with CHCl2/CH3OH (2:1), followed by solvent evaporation and DW calculation.
2.6 Gene expression analysis by quantitative RT-PCR
Liver and ileum—Total RNA was isolated from liver and ileum for TNFα, IL-1β, 
interleukin-6 (IL-6) expression; and additionally, glucose-6 phosphatase (G6P), 
phosphoenolpyruvate carboxykinase (PEPCK) and glucokinase (GcK) expression from liver 
tissue using PureLink® RNA mini kit plus on-column DNase treatment (Applied 
Biosystems, Foster City, CA). Tissue (100 mg) was homogenized with TRIzol® using 
zirconium beads in a Bead Bug homogenizer (Benchmark Scientific, Inc. Edison, NJ). First-
strand cDNA was synthetized from 2 μg total RNA using the high capacity cDNA reverse 
transcription kit plus RNase inhibitor (Applied Biosystems) with oligo-d(T)s as primers. 
PCR analyses were performed on a 7300 Real-Time PCR system using the TaqMan Assays 
(Applied Biosystems; Suppl. Table 3). Hydroxymethylbilane synthase (Hmbs) was used to 
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normalize target gene expression and effect of treatment on gene expression levels was 
evaluated by the ΔΔCt method [20].
Adipose Tissue—Inguinal fat was homogenized in QIAzol lysis reagent (Qiagen, Inc., 
Valencia, CA) using a Tekmar Tissumizer homogenizer (Model TR-10). Lysates were 
mixed with chloroform to induce phase separation, and total RNA was purified using the 
RNeasy Lipid Tissue Mini Kit (Qiagen). cDNA was synthesized from RNA using the RT2 
First Strand Kit (Qiagen). An Applied Biosystems 7900HT Fast Real-Time PCR System 
was used to conduct real time qPCR analyses. Analysis of thermogenic and lipolysis-related 
gene expression was quantified using the RT2 SYBR Green qPCR Mastermix and custom 
RT2 Profiler PCR Array (Qiagen) containing mouse primer assays (Suppl. Table 4) for: 
uncoupling protein 1 (UCP1), PR domain containing 16 (PRDM16), beta-3 adrenergic 
receptor (ADRB3), carnitine palmitoyltransferase 1b (CPT1b), cell death-inducing DFFA-
like effector A (CIDEA), peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC-1α), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and peptidyl prolyl 
isomerase H (PPIH). GAPDH and PPIH were included as endogenous reference genes, and 
PPIH was used to normalize target gene expression. The effect of treatment on relative gene 
expression levels was evaluated by the ΔΔCt method [20]. Analysis of inflammatory-related 
gene expression for adiponectin (ADPN), monocyte chemoattractant protein-1 (MCP1), 
plasminogen activator inhibitor type 1 (PAI1), lipocalin-2 (LCN2), IL-1β, IL-6, peptidyl 
prolyl isomerase A (PPIA), and peptidyl prolyl isomerase B (PPIB) was quantified using the 
SYBR supermix reagent (Takara) and primer pairs shown in Suppl. Table 5. TNFα primers 
were from Qiagen (Assay ID: PPM03113G). Standard curves were used to determine 
relative expression. Each target gene was normalized by the geometric mean of PPIA and 
PPIB. The effect of treatment on relative gene expression levels was evaluated by 
calculating fold change of treatment group versus control group for each target gene.
2.7 Immunoblot analysis
Liver and muscle tissues were prepared for immunoblot analysis as previously described 
[21]. Briefly, tissue samples were homogenized and protein concentration was measured by 
the Bio-Rad protein assay kit (Bio-Rad laboratories, Hercules, CA). Supernatants (50 μg) 
were resolved by SDS-PAGE and subjected to western blotting. The protein abundance was 
detected with antibodies against p-tyr (PY20), insulin receptor substrate 1 (IRS-1), IRS-2, 
anti-phospho-IRS-1(Tyr612)(IRS-1 p), p85 of PI 3K (PI 3K), RAC-alpha serine/threonine-
protein kinase (Akt1), RAC-beta serine/threonine-protein kinase (Akt2), phosph-
Akt1(Ser473)(Akt1 p) (Upstate Biotechnology, Lake Placid, NY), phosph-Akt2(Ser474)(Akt2 
p) (GenScript, Piscataway, NJ), sterol regulatory element binding protein-1c (SREBP-1c), 
cell death-inducing DFFA-like effector c (FSP27/CIDEA in humans), lipoprotein lipase 
(LPL), adipose triglyceride lipase (ATGL), insulin receptor beta (IRβ) (Santa Cruz 
Biotechnology, Santa Cruz, CA), glucose transporter type 4 (GLUT4) (R&D Systems, 
Minneapolis, MN), 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR), fatty acidy 
synthase (FAS) (Abcam, Cambridge, MA), and β-actin using chemiluminescence Reagent 
Plus (PerkinElmer, Boston, MA), and quantified via a densitometer. All proteins were 
normalized by β-actin, and specific protein phosphorylation was normalized by the 
corresponding protein.
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2.8 In vitro gluconeogenesis studies
H4IIE rat hepatoma cells (CRL-1548, American Type Culture Collection, Manassas, VA) 
were assayed for glucose production as previously described [22]. Cell viability was 
measured by the 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT; TCI, 
Portland, OR) assay [23]. RNA extraction, cDNA synthesis and qPCR for gene expression 
of PEPCK and G6P were performed as described above.
2.9 In vitro lipolysis assay
Murine 3T3-L1 preadipocytes were grown and differentiated as previously described [24]. 
Mature adipocytes were > 99% differentiated. Prior to performing the lipolysis assay, the 
media was changed to Dulbecco's modified Eagle's medium (DMEM) supplemented with 
5% calf serum (HyClone, Thermo Scientific, Logan, UT) for 24 – 48 hr. The adipolysis 
assay kit (EMD Millipore, Temecula, CA) was used to evaluate the ability of MC, MIC-1, 
and MIC-4 to modulate lipolysis. Briefly, cell monolayers were washed with wash solution. 
The assay was initiated by replacing the wash solution with the incubation solution 
supplemented with 2% bovine serum albumin plus vehicle (0.05% ethanol), isoproterenol 
(10 μM, positive control) MC (50, 100 μg/mL) or MICs (5, 10 μM). After 3.5 hours, the 
conditioned media was removed and assayed for free glycerol content using the Free 
glycerol assay reagent according to the kit instructions.
2.10 Statistical analysis
GraphPad Prism v.6.04 (GraphPad Software Inc., San Diego, CA) was used for all statistical 
analysis except for RER analysis which was performed using Statistical Analysis System. P 
< 0.05 was considered statistically significant. Specifics of statistical analysis are indicated 
in each figure legend.
3. Results
3.1 Effect of MC on body weight, body composition, OGTT, liver composition and lipid 
content
The VHFD + 5% MC-fed mice gained significantly less weight over the 3 month study 
compared to the VHFD-control mice (P<0.001 from 4-12 weeks) with a final average 
weight of 38.4 ± 1.0 g vs. 46.9 ± 1.0 g (mean ± SEM), respectively (Fig. 1A). All animals 
involved in the study looked healthy at the end of the study with no adverse effects noticed. 
Weekly food consumption remained stable throughout the 12 week study, averaging 2.22 ± 
0.02 g /d for VHFD + 5% MC group vs. 2.42 ± 0.05 g/d for control mice. The 5% MC diet 
contained 800 mg of MICs/kg, therefore the mice were consuming approximately 66 mg of 
MICs per d. Accumulated food intake only became significantly less in the VHFD + 5% MC 
fed group at the 12th week (P < 0.05). However, the ratio of accumulated food intake to 
body weight was significantly higher in the VHFD + 5% MC-fed mice compared to the 
VHFD group throughout the entire study (Fig. 1B). Body composition at 4, 8 and 12 weeks 
showed lower fat accumulation (Fig. 1C) and greater free fat (lean mass) as percentage of 
body weight in the VHFD + 5% MC-fed mice compared to the VHFD-fed mice (Fig. 1D). 
OGTT performed at 4, 8 and 12 weeks demonstrated lower blood glucose levels and faster 
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return to fasting levels in VHFD + 5% MC-fed mice compared to VHFD-fed mice (Fig. 2), 
corroborating previously observed lowering of blood glucose levels in diabetic rats from a 
single administration of moringa extract (200 mg/kg) [25]. Compared to fatty livers of 
VHFD-fed mice, livers from the VHFD + 5% MC-fed animals did not show the appearance 
of fatty-liver disease (Fig. 3A & 3B) as also evident from the histological comparison (Fig. 
3D & 3E). The livers of VHFD + 5% MC-fed mice weighed less (Fig. 3C) and contained 
lower levels of lipids in relation to the VHFD-fed mice (Fig. 3F). There was no significant 
difference in the lipid content as percent of dry fecal weight from the two experimental 
groups (VHFD, 0.47 ± 0.14%; VHFD + 5% MC, 0.46 ± 0.04%).
3.2 Effect of MC on blood composition, insulin sensitivity and inflammation
VHFD + 5% MC-fed mice had lower blood plasma levels of glucose regulators (insulin, 
leptin, resistin) (Fig. 4A), inflammatory cytokines (IL-1β and TNFα) (Fig. 4B), and 
cholesterol (Fig. 4C) compared to the VHFD group. When compared to VHFD-fed mice, 
VHFD + 5% MC-fed mice also had significantly higher levels of proteins involved in 
insulin signaling - IRS-1p, IRS-1 PI-3K, Akt1p and Akt2p in liver (Fig. 5A); and increased 
levels of IRS-1p, IRS-1, IRS-2, IR β, Akt1 and GLUT4 in muscle (Fig. 5B). Reduced gene 
expression of pro-inflammatory markers, TNFα, IL-6, IL-1β, were observed in the liver 
(Fig. 6A) and ileum (Fig. 6B) tissue from the VHFD + 5% MC-fed mice compared to the 
VHFD group. Similarly, in adipose tissue, gene expression of TNFα was reduced while 
adiponectin had enhanced expression in the treatment mice relative to the VHFD controls 
(Fig 6C).
3.3 Effect of MC and MICs on glucose metabolism and OGTT
MC and MICs significantly reduced glucose production by approximately 60% in HII4E 
liver cells at 10 μg/mL and 1 μM, respectively (P < 0.001). MIC-1 and 4 demonstrated 
superior activity to SF at the same concentrations (Fig. 7A). To further explore the activity 
of MICs in comparison to the prescription drug metformin, MIC-4 and metformin were 
tested over a range of 5 concentrations, showing IC50 of glucose production at 7 μM for 
MIC-4 vs 800 μM for metformin (Fig. 7B). MC and MICs also significantly decreased 
expression of G6P and PEPCK in HII4E liver cells relative to the vehicle (Fig. 7C). G6P 
expression was significantly lower in the hepatic tissue of VHFD + 5% MC-fed mice 
compared to the controls (Fig. 7D). Glucose lowering effects of MC were further tested in 
vivo by the acute OGTT, to eliminate the weight difference variable in the long-term feeding 
study. The acute OGTT resulted in significantly lower blood glucose levels at 15 and 30 
minutes in the MC-gavaged mice (2 g/kg) compared to the vehicle (Fig. 7E).
3.4 Effect of MC and MICs on lipolysis and thermogenesis
To better understand the reduced weight gain in MC-fed mice, the mechanisms of lipolysis 
and thermogenesis were explored in vitro and in vivo. MC at 50 μg/mL slightly increased 
production of glycerol in adipocytes, but at a higher concentration (100 μg/mL) no 
significant increase was observed. MIC-1 and MIC-4 did not demonstrate any significant 
lipolytic activity (Fig. 8A). Inguinal adipose tissues from the VHFD + 5% MC-fed mice 
showed increased gene expression of PRDM16, ADRB3, PGC-1α, but decreased expression 
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of UCP1 compared to VHFD-fed mice (Fig. 8B). Hepatic tissue from VHFD + 5% MC-fed 
mice showed relatively lower GcK gene expression (Fig. 8C), lower protein levels of FAS, 
SREBP1c, and FSP27 and increased levels of ATGL relative to control mice (Fig. 8D). To 
understand if the increased expression of in vitro and in vivo lipolytic and thermogenic gene 
expression results would translate to increased energy expenditure and fat oxidation in vivo, 
an additional 7 d study was conducted in TSE metabolic chambers. Mice fed a VHFD or a 
VHFD + 3.3% MC (containing the same concentration of MICs as the 5% diet in the 3 
month study) showed no differences in O2 consumption, or rearing activity between the two 
cohorts (data not shown). However, the VHFD + 3.3% MC-fed mice did gain less weight, 
had lower food consumption during the light period, and exhibited a lower respiratory 
exchange ratio (RER) of 0.805 compared to 0.812 in the control group (P < 0.001) (Fig. 8E).
4. Discussion
This study provides justification and preliminary mechanistic evidence for the uses of 
moringa as a dietary agent in preventing T2D by demonstrating that MIC-enriched MC 
caused significant reduction in weight gain, hepatic adiposity, gluconeogenesis, insulin, 
cholesterol, and inflammatory markers; and increase in insulin signaling sensitivity and 
lipolysis. Our study also provides support for the role of MICs as primary antidiabetic 
actives in moringa. The most notable result of the long-term feeding study was the very 
significant reduction in weight gain observed in the MC-fed mice. Healthy C57BL/6J mice 
fed a low fat diet (10% kcal from fat) typically gain 25-32% less weight than mice on a 
VHFD [21, 26, 27]. In this experiment the MC-fed mice gained 18% less weight than the 
VHFD-fed mice, demonstrating almost complete abolition of excess weight gain caused by 
the VHFD, without any other observable side effects. Slight differences in accumulated food 
intake or food aversion cannot explain the reduced weight gain in MC-fed mice, because the 
ratio of accumulated food intake to body weight was actually higher in the VHFD + 5% 
MC-fed mice compared to the VHFD group. Previous in vitro work demonstrated MICs and 
MC possess anti-inflammatory activity manifested as decreased IL-1β and TNFα expression 
and nitric oxide (NO) production [2]; effects that were also observed in this in vivo study. 
TNFα over expression was identified decades ago as a contributing factor to obesity-
induced T2D [28], particularly by studies showing TNFα knockout mice had increased 
insulin sensitivity [29-31]. However, only slight decreases in body weight gain were noted 
in these studies, indicating the anti-inflammatory effects of MICs alone are not likely 
responsible for anti-obesity effects observed by MC treatment. However, MICs are very 
effective in blocking glucose production in HII4E hepatocytes, showing activity at 
nanomolar concentrations (Fig 7A-B) and being close to two orders of magnitude more 
active than metformin (Fig 7B). Because MICs were able to decrease PEPCK and G6P gene 
expression at similarly low concentrations it is tempting to speculate that MICs act via 
blocking these rate-limiting steps in liver gluconeogenesis. Decreased G6P and PEPCK gene 
expression was also observed in liver tissue from the MC feeding study, further supporting 
this mode of action (Fig 7D). In a long term, reduced gluconeogenesis may contribute to 
improved insulin sensitivity, as metformin's inhibition of gluconeogenesis [33] has been a 
successful target for treating T2D [34], although other studies suggest that metformin may 
have other modes of action [35-37]. Additional symptoms of T2D include impaired insulin 
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signaling and insulin sensitivity and increased serum levels of insulin, leptin, resistin, TG, 
and cholesterol [21, 38-41]; all of which were reduced by MC treatment. Similarly, MC-fed 
mice showed activation of components of insulin signaling pathway, such as increased 
levels of IRSs, protein kinases, PI3K, and GLUT4 in liver and muscle tissue.
Before suggesting decreased gluconeogensis as a primary mechanism of action of MC, we 
investigated whether MICs and MC may also increase lipolysis and theromogenesis, which 
may also contribute to lower fat accumulation and body mass. We observed mild effect of 
MC and MIC-1 and 4 treatment on increased glycerol production in adipocytes (Fig 8A), 
indicative of lipolytic breakdown of TG into free fatty acids and glycerol. However, small 
magnitude and poor dose dependency of the effect made lipolysis is an unlikely primary 
target for MICs action. From the animal studies we noted relatively lower hepatic GcK gene 
expression and high ATGL protein levels in MC-fed mice (Fig. 8C). High-fat diet has been 
shown to up-regulate GcK and through neural signaling subsequently down regulate 
thermogenesis-related genes in brown adipose tissue (BAT) and increase overall adiposity 
[43, 44]. White adipose tissue (WAT) is able to differentiate into depots of brown-like 
adipocytes, often called beige fat [45]. Indeed, the inguinal WAT from mice in long-term 
study did have detectable levels of browning genes (Fig 8B). MC-fed mice had significantly 
increased expression of PRDM16 and PGC-1α, transcriptional regulators in beige fat 
formation and lipolysis [46], but did not show the usual corresponding increase of UCP1. 
This questions the possibility that MC-treatment directly increases thermogenesis. More 
compelling is the 4-fold increase in ADRB3 expression from MC-fed compared to control 
mice. ADRB3 plays a major regulatory role in lipolysis through interaction with 
catecholamines [47]. In the current study it is more likely that greater ADRB3 expression is 
linked to increased lipolysis which proceeds to production of ATP, rather than heat, due to 
the conflicting data on PRDM16, PGC1-α with UCP1 expression. Nonetheless, MC-
mediated lipolysis, whether direct or indirect, was further corroborated by 1) hepatic down 
regulation of lipogenic proteins (FAS, SREBP1 and FSP27) and up regulation of ATGL, an 
important hepatic lipase responsible for TG turnover [48] (Fig. 8D), and 2) a significantly 
lower RER measured in MC-fed mice compared to the control, indicative of increased fatty 
acid oxidation relative to carbohydrate oxidation. The later observation suggests that MC-
treatment enhances fat oxidation at the expense of carbohydrate oxidation.
Collectively, the results of in vitro and in vivo experiments provide support for the 
hypothesis that MICs are the primary biologically active anti-obesity and anti-diabetes 
constituents of MC whose primary mechanism of action is the inhibition of liver 
gluconeogenesis, which directly or indirectly results in systemically increased insulin 
signaling and sensitivity. These effects may in turn cause increased lipolysis, higher ratio of 
fat/carbohydrate oxidation, ultimately resulting in reduced lipid accumulation in the liver 
and body. These conclusions, combined with previous data on MICs anti-inflammatory 
effects [2], suggest that MC and MICs may have beneficial effects for prevention and 
treatment of obesity and T2D.
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Abbreviations
ADPN adiponectin
ADRB3 beta-3 adrenergic receptor
Akt1 p phosph-Akt1(Ser473)
Akt1 RAC-alpha serine/threonine-protein kinase
Akt2 p phosph-Akt2(Ser474)
Akt2 RAC-beta serine/threonine-protein kinase
ATGL adipose triglyceride lipase
CIDEA cell death-inducing DFFA-like effector A
CIDEA cell death-inducing DFFA-like effector c
CPT1b carnitine palmitoyltransferase 1b
DW dry weight










IRS-1 insulin receptor substrate 1
IRS-2 insulin receptor substrate 2
IRβ insulin receptor beta
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MCP-1 monocyte chemoattractant protein-1
MICs moringa isothiocyanates
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
OGTT oral glucose tolerance test
PAI1 plasminogen activator inhibitor type 1
PEPCK phosphoenolpyruvate carboxykinase
PGC-1α peroxisome proliferator-activated receptor gamma coactivator 1-alpha
PI 3K p85 of PI 3K
PPIA peptidyl prolyl isomerase A
PPIB peptidyl prolyl isomerase B
PPIH peptidyl prolyl isomerase H
PRDM16 PR domain containing 16
PY20 p-tyr (PY20)
RER respiratory exchange ratio
SF sulforaphane
SREBP-1c sterol regulatory element binding protein-1c
TG triglycerides
TNFα tumor necrosis factor alpha
UCP1 uncoupling protein 1
VHFD very high fat diet
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Body weight gain (A), ratio of accumulated food intake to body weight (B), fat mass (C) and 
free fat mass (D) in VHFD and VHFD + 5% MC-fed mice. n=12 mice per group, Data are 
means ± SEM. Comparisons to controls were made by Welch's test. *P < 0.05; **P < 0.01; 
***P < 0.001.
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Oral glucose tolerance test performed at 4 (A), 8 (B) and 12 (C) weeks on a mice fed a 
VHFD, VHFD + 5% MC, and a VHDF gavaged with 300mg/kg metformin on the day of 
OGTT. Area Under the Curve of OGTT at 4, 8, and 12 weeks (D). n = 12 mice per group, 
except for metformin group where n=6 and only shown as a reference group. Data are means 
± SEM. Comparisons were made by a 1-way ANOVA followed by Tukey's posthoc test. 
Significant differences (p < 0.05) between sample sets are signified by letters; different 
letters indicate significant difference between sample sets, while the same letter or absence 
of a letter indicates no difference.
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Gross examination of liver samples from VHFD-fed mice (A) and VHFD + 5% MC-fed 
mice (B). Liver weight in VHFD and VHFD + 5% MC (n=12,) (C) Data are means ± SEM. 
**: p<.01. Histological examination of liver samples from VHFD (D) and VHFD + 5% MC 
(E). Fat content in liver from VHFD-fed mice and VHFD + 5% MC fed mice (n=12) (F). 
Comparisons to controls were made by Welch's test. Data are means ± SEM. **P < 0.01; 
***P < 0.001.
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Blood plasma expression of insulin, leptin, resistin (A), IL-1β, TNFα (B), total cholesterol 
and triglycerides (C) in VHFD and VHFD + 5% MC-fed mice. n=12 mice per group except 
for IL-1β and TNFα where n=5, undetectable levels below 2.4 pg/mL were excluded. 
Comparisons to controls were made by Welch's test. Data are means ± SEM. *P < 0.05; **P 
< 0.01.
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Insulin signaling protein levels in liver (A) and skeletal muscle (B) from VHFD +5% MC-
fed mice relative to VHFD-fed mice (dashed line). n=12 mice per group, Data are means ± 
SEM. Comparisons to controls were made by Welch's test. *P < 0.05; **P < 0.01; ***P < 
0.001.
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Gene expression of inflammatory markers in liver (A), ileum (B), and adipose tissue (C) of 
VHFD and VHFD + 5% MC-fed mice. n = 8-12, Data are means ± SEM. Comparisons to 
controls were made by Welch's test for liver, ileum, and adipose tissue. *P < 0.05.
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Effect of MICs, SF and MC on glucose metabolism in vitro (A, B, C) and in vivo (D, E). 
Effects of MC, MIC-1, MIC-4 and sulforaphane (SF) on glucose production (A, B) and gene 
expression of G6P and PEPCK in HII4E liver cells; n=3 (C). Expression of G6P and PEPCK 
in hepatic tissue of VHFD and VHFD + 5% MC-fed mice (D) n=12. Acute OGTT test in 
VHFD-fed mice gavaged with 2g/kg of MC (E) n = 6. Comparisons to controls were made 
by Dunnett's test for A and C, and a t-test for D. Data are means ± SEM. *: p<.05, **: p<.01, 
***: p<.001. Comparisons for E were made by a 1-way ANOVA followed by Tukey's 
posthoc test. Significant differences (p < 0.05) between sample sets are signified by letters; 
different letters indicate significant difference between sample sets, while the same letter or 
absence of a letter indicates no difference.
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Effect of MICs and MC on lipolysis and thermogenesis in vitro (A) and in vivo (B-E). 
Production of glycerol in adipocytes treated with MC, MIC-1 and MIC-4; n = 3 (A). 
Expression of thermogenic and lipolytic genes in adipose tissue (B) and hepatic GcK (C) 
from VHFD and VHFD + 5% MC-fed mice for 3 months; n = 12. Hepatic lipid 
metabolizing protein levels from VHFD and VHFD + 5% MC-fed mice for 3 months; n = 12 
(D). RER in mice switched to a VHFD + 3.3% MC after 7 days compared to mice that 
remained on a VHFD (n=12) (E). Data are means ± SEM. Comparisons to controls were 
made by t-test for A, Welch's test for B, C D and ANCOVA for E. *: p<.05, **: p<.01, ***: 
p<.001.
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